References
Key articles
National Institute for Health and Care Excellence. Atopic eczema in under 12s: diagnosis and management. Jun 2023 [internet publication].Full text
European Dermatology Forum. Living EuroGuiDerm guideline for the systemic treatment of atopic eczema. Oct 2023 [internet publication].Full text
Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024 Feb;90(2):e43-56.Full text Abstract
Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023 Jan 11:S0190-9622(23)00004-X.Full text Abstract
Reference articles
1. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003 Dec;112(6 Suppl):S118-27. Abstract
2. Kim JP, Chao LX, Simpson EL, et al. Persistence of atopic dermatitis (AD): a systematic review and meta-analysis. J Am Acad Dermatol. 2016 Oct;75(4):681-7;e11.Full text Abstract
3. Chopra R, Vakharia PP, Sacotte R, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017 Nov;177(5):1316-21. Abstract
4. National Institute for Health and Care Excellence. Dupilumab for treating moderate to severe atopic dermatitis. Aug 2018 [internet publication].Full text
5. Agache I, Akdis CA, Akdis M, et al. EAACI biologicals guidelines: dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy. 2021 Apr;76(4):988-1009. Abstract
6. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66 Suppl 1:8-16.Full text Abstract
7. Leung D, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest. 2004 Mar;113(5):651-7.Full text Abstract
8. Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019 Mar;139(3):583-90.Full text Abstract
9. Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018 Sep;121(3):340-7.Full text Abstract
10. Williams H. Atopic dermatitis. N Engl J Med. 2005 Jun 2;352(22):2314-24. Abstract
11. Thomsen SF. Epidemiology and natural history of atopic diseases. Eur Clin Respir J. 2015 Mar 24;2(1):24642.Full text Abstract
12. Odhiambo JA, Williams HC, Clayton TO, et al; ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009 Dec;124(6):1251-8.e23.Full text Abstract
13. Williams H, Stewart A, von Mutius E, et al; International Study of Asthma and Allergies in Childhood (ISAAC) Phase One and Three Study Groups. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008 Apr;121(4):947-54.e15.Full text Abstract
14. Bylund S, von Kobyletzki LB, Svalstedt M, et al. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020 Jun 9;100(12):adv00160.Full text Abstract
15. Hirano SA, Murray SB, Harvey VM. Reporting, representation, and subgroup analysis of race and ethnicity in published clinical trials of atopic dermatitis in the United States between 2000 and 2009. Pediatr Dermatol. 2012 Nov-Dec;29(6):749-55. Abstract
16. Brunner PM, Guttman-Yassky E. Racial differences in atopic dermatitis. Ann Allergy Asthma Immunol. 2019 May;122(5):449-55.Full text Abstract
17. Burbank AJ, Hernandez ML, Jefferson A, et al. Environmental justice and allergic disease: a work group report of the AAAAI Environmental Exposure and Respiratory Health Committee and the Diversity, Equity and Inclusion Committee. J Allergy Clin Immunol. 2023 Mar;151(3):656-70.Full text Abstract
18. McKenzie C, Silverberg JI. The prevalence and persistence of atopic dermatitis in urban United States children. Ann Allergy Asthma Immunol. 2019 Aug;123(2):173-8.e1. Abstract
19. Flohr C, Yeo L. Atopic dermatitis and the hygiene hypothesis revisited. Curr Probl Dermatol. 2011;41:1-34. Abstract
20. Schultz Larsen F, Diepgen T, Svensson A. The occurrence of atopic dermatitis in north Europe: an international questionnaire study. J Am Acad Dermatol. 1996 May;34(5 pt 1):760-4. Abstract
21. Meagher LJ, Wines NY, Cooper AJ. Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy. Australas J Dermatol. 2002 Nov;43(4):247-54. Abstract
22. Morar N, Cookson W, Harper JI, et al. Filaggrin mutations in children with severe atopic dermatitis. J Invest Dermatol. 2007 Jul;127(7):1667-72.Full text Abstract
23. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006 Apr;38(4):441-6. Abstract
24. McLean WH. Filaggrin failure: from ichthyosis vulgaris to atopic eczema and beyond. Br J Dermatol. 2016 Oct;175(Suppl 2):4-7.Full text Abstract
25. McGrath JA. Filaggrin and the great epidermal barrier grief. Australas J Dermatol. 2008 May;49(2):67-73; quiz 73-4. Abstract
26. Løset M, Brown SJ, Saunes M, et al. Genetics of atopic dermatitis: from DNA sequence to clinical relevance. Dermatology. 2019;235(5):355-64.Full text Abstract
27. Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. Expert Rev Clin Immunol. 2017 Jan;13(1):15-26.Full text Abstract
28. Tamagawa-Mineoka R, Katoh N. Atopic dermatitis: identification and management of complicating factors. Int J Mol Sci. 2020 Apr 11;21(8):2671.Full text Abstract
29. Geoghegan JA, Irvine AD, Foster TJ. Staphylococcus aureus and atopic dermatitis: a complex and evolving relationship. Trends Microbiol. 2018 Jun;26(6):484-97. Abstract
30. Liu X, Yang G, Luo M, et al. Serum vitamin E levels and chronic inflammatory skin diseases: a systematic review and meta-analysis. PLoS One. 2021;16(12):e0261259.Full text Abstract
31. Havmose MS, Kezic S, Uter W, et al. Prevalence and incidence of hand eczema in hairdressers - a systematic review and meta-analysis of the published literature from 2000-2021. Contact Dermatitis. 2022 Apr;86(4):254-65.Full text Abstract
32. Jabbar-Lopez ZK, Ung CY, Alexander H, et al. The effect of water hardness on atopic eczema, skin barrier function: a systematic review, meta-analysis. Clin Exp Allergy. 2021 Mar;51(3):430-51. Abstract
33. Calov M, Alinaghi F, Hamann CR, et al. The association between season of birth and atopic dermatitis in the northern hemisphere: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2020 Feb;8(2):674-80.e5. Abstract
34. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007 Jul;120(1):150-5. Abstract
35. Mao Y, Yang C, Tang L, et al. Increased expression of T helper 17 cells and interleukin-17 in atopic dermatitis: a systematic review and meta-analysis. Ann Palliat Med. 2021 Dec;10(12):12801-9.Full text Abstract
36. Carlsten C, Dimich-Ward H, Ferguson A, et al. Atopic dermatitis in a high-risk cohort: natural history, associated allergic outcomes, and risk factors. Ann Allergy Asthma Immunol. 2013 Jan;110(1):24-8. Abstract
37. Knudgaard MH, Andreasen TH, Ravnborg N, et al. Rhinitis prevalence and association with atopic dermatitis: a systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2021 Jul;127(1):49-56.e1. Abstract
38. Ravnborg N, Ambikaibalan D, Agnihotri G, et al. Prevalence of asthma in patients with atopic dermatitis: a systematic review and meta-analysis. J Am Acad Dermatol. 2021 Feb;84(2):471-8. Abstract
39. Li H, Dai T, Liu C, et al. Phenotypes of atopic dermatitis and the risk for subsequent asthma: a systematic review and meta-analysis. J Am Acad Dermatol. 2022 Feb;86(2):365-72. Abstract
40. Kantor R, Kim A, Thyssen JP, et al. Association of atopic dermatitis with smoking: a systematic review and meta-analysis. J Am Acad Dermatol. 2016 Dec;75(6):1119-25;e1.Full text Abstract
41. Kramer MS, Kakuma R. Maternal dietary antigen avoidance during pregnancy or lactation, or both, for preventing or treating atopic disease in the child. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD000133.Full text Abstract
42. Cuello-Garcia CA, Brożek JL, Fiocchi A, et al. Probiotics for the prevention of allergy: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2015 Oct;136(4):952-61.Full text Abstract
43. Makrgeorgou A, Leonardi-Bee J, Bath-Hextall FJ, et al. Probiotics for treating eczema. Cochrane Database Syst Rev. 2018 Nov 21;(11):CD006135.Full text Abstract
44. Tan-Lim CSC, Esteban-Ipac NAR, Recto MST, et al. Comparative effectiveness of probiotic strains on the prevention of pediatric atopic dermatitis: a systematic review and network meta-analysis. Pediatr Allergy Immunol. 2021 Aug;32(6):1255-70. Abstract
45. Kelleher MM, Phillips R, Brown SJ, et al. Skin care interventions in infants for preventing eczema and food allergy. Cochrane Database Syst Rev. 2022 Nov 14;(11):CD013534.Full text Abstract
46. National Institute for Health and Care Excellence. Atopic eczema in under 12s: diagnosis and management. Jun 2023 [internet publication].Full text
47. Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups - variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018 Apr;27(4):340-57.Full text Abstract
48. Silvestre Salvador JF, Romero-Pérez D, Encabo-Durán B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. 2017;27(2):78-88.Full text Abstract
49. Pugliarello S, Cozzi A, Gisondi P, et al. Phenotypes of atopic dermatitis. J Dtsch Dermatol Ges. 2011 Jan;9(1):12-20.Full text Abstract
50. Eigenmann PA, Sicherer SH, Borkowski TA, et al. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics. 1998 Mar;101(3):E8. Abstract
51. European Dermatology Forum. Living EuroGuiDerm guideline for the systemic treatment of atopic eczema. Oct 2023 [internet publication].Full text
52. Singh AM, Anvari S, Hauk P, et al. Atopic dermatitis and food allergy: best practices and knowledge gaps - a work group report from the AAAAI Allergic Skin Diseases Committee and Leadership Institute Project. J Allergy Clin Immunol Pract. 2022 Mar;10(3):697-706.Full text Abstract
53. Chang A, Robison R, Cai M, et al. Natural history of food-triggered atopic dermatitis and development of immediate reactions in children. J Allergy Clin Immunol Pract. 2016 Mar-Apr;4(2):229-36.e1.Full text Abstract
54. David TJ. Anaphylactic shock during elimination diets for severe atopic eczema. Arch Dis Child. 1984 Oct;59(10):983-6.Full text Abstract
55. Eigenmann PA, Beyer K, Lack G, et al. Are avoidance diets still warranted in children with atopic dermatitis? Pediatr Allergy Immunol. 2020 Jan;31(1):19-26. Abstract
56. Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014 Dec;71(6):1218-33.Full text Abstract
57. Du Toit G, Roberts G, Sayre PH, et al; LEAP Study Team. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015 Feb 26;372(9):803-13.Full text Abstract
58. Beattie PE, Green C, Lowe G, et al. Which children should we patch test? Clin Exp Dermatol. 2007 Jan;32(1):6-11. Abstract
59. Milingou M, Tagka A, Armenaka M, et al. Patch tests in children: a review of 13 years of experience in comparison with previous data. Pediatr Dermatol. 2010 May-Jun;27(3):255-9. Abstract
60. Pigatto P, Martelli A, Marsili C, et al. Contact dermatitis in children. Ital J Pediatr. 2010 Jan 13;36:2.Full text Abstract
61. Owen JL, Vakharia PP, Silverberg JI. The role and diagnosis of allergic contact dermatitis in patients with atopic dermatitis. Am J Clin Dermatol. 2018 Jun;19(3):293-302.Full text Abstract
62. Jacob SE, Burk CJ, Connelly EA. Patch testing: another steroid-sparing agent to consider in children. Pediatr Dermatol. 2008 Jan-Feb;25(1):81-7. Abstract
63. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014 Feb;70(2):338-51.Full text Abstract
64. Barnetson R, Rogers M. Childhood atopic eczema. BMJ. 2002 Jun 8;324(7350):1376-9. Abstract
65. Piloto Valdés L, Gómez Echevarría AH, Valdés Sánchez AF, et al. Atopic dermatitis: findings of skin biopsies. Allergol Immunopathol (Madr). 1990 Nov-Dec;18(6):321-4. Abstract
66. Arora P, Rudnicka L, Sar-Pomian M, et al. Scabies: a comprehensive review and current perspectives. Dermatol Ther. 2020 Jul;33(4):e13746. Abstract
67. Weinstock MA, Horm JW. Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA. 1988 Jul 1;260(1):42-6. Abstract
68. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermatol Vereneol. 1980;60(92 suppl):44-47.Full text
69. De D, Kanwar AJ, Handa S. Comparative efficacy of Hanifin and Rajka's criteria and the UK working party's diagnostic criteria in diagnosis of atopic dermatitis in a hospital setting in North India. JEADV. 2006 Aug;20(7):853-9. Abstract
70. Vakharia PP, Chopra R, Silverberg JI. Systematic review of diagnostic criteria used in atopic dermatitis randomized controlled trials. Am J Clin Dermatol. 2018 Feb;19(1):15-22. Abstract
71. Johnke H, Vach W, Norberg LA, et al. A comparison between criteria for diagnosing atopic eczema in infants. Br J Dermatol. 2005 Aug;153(2):352-8. Abstract
72. Williams HC, Burney PG, Pembroke AC, et al. Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting. Br J Dermatol. 1996 Jul;135(1):12-7. Abstract
73. Williams HC, Burney PG, Hay RJ, et al. The U.K. Working Party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994 Sep;131(3):383-96. Abstract
74. Fleming S, Bodner C, Devereux G, et al. An application of the United Kingdom Working Party diagnostic criteria for atopic dermatitis in Scottish infants. J Invest Dermatol. 2001 Dec;117(6):1526-30. Abstract
75. Darsow U, Wollenberg A, Simon D, et al; European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol. 2010 Mar;24(3):317-28.Full text Abstract
76. Simpson EL. Atopic dermatitis: a review of topical treatment options. Cur Med Res Opin. 2010 Mar;26(3):633-40. Abstract
77. Kosse RC, Bouvy ML, Daanen M, et al. Adolescents' perspectives on atopic dermatitis treatment - experiences, preferences, and beliefs. JAMA Dermatol. 2018 Jul 1;154(7):824-7.Full text Abstract
78. van Zuuren EJ, Fedorowicz Z, Christensen R, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017 Feb 6;(2):CD012119.Full text Abstract
79. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024 Feb;90(2):e43-56.Full text Abstract
80. Yu SH, Drucker AM, Lebwohl M, et al. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018 Apr;78(4):733-40. Abstract
81. Eckert L, Gupta S, Amand C, et al. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017 Aug;77(2):274-9.Full text Abstract
82. Teasdale E, Muller I, Sivyer K, et al. Views and experiences of managing eczema: systematic review and thematic synthesis of qualitative studies. Br J Dermatol. 2021 Apr;184(4):627-37.Full text Abstract
83. Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023 Jan 11:S0190-9622(23)00004-X.Full text Abstract
84. Czarnowicki T, Malajian D, Khattri S, et al. Petrolatum: barrier repair and antimicrobial responses underlying this "inert" moisturizer. J Allergy Clin Immunol. 2016 Apr;137(4):1091-102.Full text Abstract
85. Nicol NH, Boguniewicz M, Strand M, et al. Wet wrap therapy in children with moderate to severe atopic dermatitis in a multidisciplinary treatment program. J Allergy Clin Immunol Pract. Jul-Aug 2014;2(4):400-6. Abstract
86. Del Rosso JQ, Bhambri S. Daily application of fluocinonide 0.1% cream for the treatment of atopic dermatitis. J Clin Aesthet Dermatol. 2009 Sep;2(9):24-32.Full text Abstract
87. Lax SJ, Harvey J, Axon E, et al. Strategies for using topical corticosteroids in children and adults with eczema. Cochrane Database Syst Rev. 2022 Mar 11;(3):CD013356.Full text Abstract
88. El Hachem M, Gesualdo F, Ricci G, et al. Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey. Ital J Pediatr. 2017 Feb 28;43(1):22.Full text Abstract
89. Smith SD, Hong E, Fearns S, et al. Corticosteroid phobia and other confounders in the treatment of childhood atopic dermatitis explored using parent focus groups. Australas J Dermatol. 2010 Aug;51(3):168-74. Abstract
90. Veenje S, Osinga H, Antonescu I, et al. Focus group parental opinions regarding treatment with topical corticosteroids on children with atopic dermatitis. Allergol Immunopathol (Madr). Mar-Apr 2019;47(2):166-71.Full text Abstract
91. Matheson R, Kempers S, Breneman D, et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. J Drugs Dermatol. 2008 Mar;7(3):266-71. Abstract
92. Hwang J, Lio PA. Topical corticosteroid withdrawal ('steroid addiction'): an update of a systematic review. J Dermatolog Treat. 2022 May;33(3):1293-8. Abstract
93. Hajar T, Leshem YA, Hanifin JM, et al; the National Eczema Association Task Force. A systematic review of topical corticosteroid withdrawal ("steroid addiction") in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015 Mar;72(3):541-9.e2. Abstract
94. Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol. 2007 Feb;156(2):203-21.Full text Abstract
95. Carbone A, Siu A, Patel R. Pediatric atopic dermatitis: a review of the medical management. Ann Pharmacother. 2010 Sep;44(9):1448-58. Abstract
96. Jeziorkowska R, Sysa-Jędrzejowska A, Samochocki Z. Topical steroid therapy in atopic dermatitis in theory and practice. Postepy Dermatol Alergol. 2015 Jun 10;32(3):162-6. Abstract
97. Sher LG, Chang J, Patel IB, et al. Relieving the pruritus of atopic dermatitis: a meta-analysis. Acta Derm Venereol. 2012 Sep;92(5):455-61. Abstract
98. Cury Martins J, Martins C, Aoki V, et al. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015 Jul 1;(7):CD009864.Full text Abstract
99. Paller AS, Fölster-Holst R, Chen SC, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020 Aug;83(2):375-81.Full text Abstract
100. Wu PC, Huang IH, Liu CW, et al. Topical calcineurin inhibitors and risk of lymphoma: a systematic review and meta-analysis. J Dtsch Dermatol Ges. 2021 Sep;19(9):1265-9.Full text Abstract
101. Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014 Jul 10;371(2):130-9.Full text Abstract
102. Yang H, Wang J, Zhang X, et al. Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2019 May 1;155(5):585-93.Full text Abstract
103. Draelos ZD, Stein Gold LF, Murrell DF, et al. Post hoc analyses of the effect of crisaborole topical ointment, 2% on atopic dermatitis: associated pruritus from phase 1 and 2 clinical studies. J Drugs Dermatol. 2016 Feb;15(2):172-6. Abstract
104. Eichenfield LF, Gower RG, Xu J, et al. Once-daily crisaborole ointment, 2%, as a long-term maintenance treatment in patients aged ≥ 3 months with mild-to-moderate atopic dermatitis: a 52-week clinical study. Am J Clin Dermatol. 2023 Jul;24(4):623-35.Full text Abstract
105. Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. Allergy Clin Immunol. 2020 Feb;145(2):572-82.Full text Abstract
106. Kim BS, Sun K, Papp K, et al. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol. 2020 Jun;82(6):1305-13.Full text Abstract
107. Nakagawa H, Nemoto O, Igarashi A, et al. Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. J Allergy Clin Immunol. 2019 Dec;144(6):1575-83.Full text Abstract
108. Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020 Apr;82(4):823-31.Full text Abstract
109. Sideris N, Paschou E, Bakirtzi K, et al. New and upcoming topical treatments for atopic dermatitis: a review of the literature. J Clin Med. 2022 Aug 24;11(17):4974.Full text Abstract
110. Chu DK, Schneider L, Asiniwasis RN, et al; AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024 Mar;132(3):274-312.Full text Abstract
111. Gong X, Chen X, Kuligowski ME, et al. Pharmacokinetics of ruxolitinib in patients with atopic dermatitis treated with ruxolitinib cream: data from phase II and III studies. Am J Clin Dermatol. 2021 Jul;22(4):555-66.Full text Abstract
112. George SM, Karanovic S, Harrison DA, et al. Interventions to reduce Staphylococcus aureus in the management of eczema. Cochrane Database Syst Rev. 2019 Oct 29;(10):CD003871.Full text Abstract
113. Musters AH, Mashayekhi S, Harvey J, et al. Phototherapy for atopic eczema. Cochrane Database Syst Rev. 2021 Oct 28;(10):CD013870.Full text Abstract
114. British Association of Dermatologists. Service guidance and standards for the use of phototherapy. Sep 2022 [internet publication].Full text
115. Elsner P, Agner T. Hand eczema: treatment. J Eur Acad Dermatol Venereol. 2020 Jan;34 Suppl 1:13-21.Full text Abstract
116. US Food and Drug Administration. Protopic medication guide. 2006 [internet publication].Full text
117. Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017 Oct;77(4):623-33.Full text Abstract
118. Schmitt J, Schäkel K, Schmitt N, et al. Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol. 2007;87(2):100-11. Abstract
119. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016 Dec 15;375(24):2335-48.Full text Abstract
120. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017 Jun 10;389(10086):2287-303. Abstract
121. de Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018 May;178(5):1083-101.Full text Abstract
122. Agache I, Song Y, Posso M, et al. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. Allergy. 2021 Jan;76(1):45-58.Full text Abstract
123. Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, et al. Systemic treatments for eczema: a network meta-analysis. Cochrane Database Syst Rev. 2020 Sep 14;(9):CD013206.Full text Abstract
124. Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020 Jun 1;156(6):659-67.Full text Abstract
125. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1409-31.Full text Abstract
126. Strober B, Mallya UG, Yang M, et al. Treatment outcomes associated with dupilumab use in patients with atopic dermatitis: 1-year results from the RELIEVE-AD Study. JAMA Dermatol. 2022 Feb 1;158(2):142-50.Full text Abstract
127. Halling AS, Loft N, Silverberg JI, et al. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021 Jan;84(1):139-47. Abstract
128. Wollenberg A, Blauvelt A, Guttman-Yassky E, et al; ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021 Mar;184(3):437-49.Full text Abstract
129. ClinicalTrials.gov. Tralokinumab monotherapy for adolescent subjects with moderate to severe atopic dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6). NCT03526861. May 2023 [internet publication].Full text
130. Silverberg JI, Toth D, Bieber T, et al; ECZTRA 3 study investigators. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021 Mar;184(3):450-63.Full text Abstract
131. Silverberg JI, Adam DN, Zirwas M, et al. Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: an ECZTRA 3 post hoc analysis. Am J Clin Dermatol. 2022 Jul;23(4):547-59.Full text Abstract
132. Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol. 2022 May 1;158(5):523-32.Full text Abstract
133. Simpson EL, Merola JF, Silverberg JI, et al. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol. 2022 Dec;187(6):888-99.Full text Abstract
134. Arora CJ, Khattak FA, Yousafzai MT, et al. The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: a systematic review and meta-analysis. Dermatol Ther. 2020 Jul;33(4):e13685. Abstract
135. Mostafa N, Phan K, Lai B, et al. Comparing quality of life outcomes of JAK inhibitors and biological treatments for atopic dermatitis: a systematic review and network meta-analysis. Expert Rev Clin Pharmacol. 2021 Nov;14(11):1435-44. Abstract
136. Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021 Jun 5;397(10290):2151-68. Abstract
137. Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021 Jun 5;397(10290):2169-81. Abstract
138. Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol. 2022 Apr 1;158(4):404-13.Full text Abstract
139. Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020 Aug 1;156(8):863-73.Full text Abstract
140. Silverberg JI, Thyssen JP, Simpson EL, et al. Impact of oral abrocitinib monotherapy on patient-reported symptoms and quality of life in adolescents and adults with moderate-to-severe atopic dermatitis: a pooled analysis of patient-reported outcomes. Am J Clin Dermatol. 2021 Jul;22(4):541-54.Full text Abstract
141. Thyssen JP, Yosipovitch G, Paul C, et al. Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2022 Mar;36(3):434-43.Full text Abstract
142. European Medicines Agency. Janus kinase inhibitors (JAKi) - referral. Mar 2023 [internet publication].Full text
143. US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. Dec 2021 [internet publication].Full text
144. Siegels D, Heratizadeh A, Abraham S, et al. Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis. Allergy. 2021 Apr;76(4):1053-76. Abstract
145. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007 May;21(5):606-19. Abstract
146. Roekevisch E, Spuls PI, Kuester D, et al. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014 Feb;133(2):429-38. Abstract
147. Yousaf M, Ayasse M, Ahmed A, et al. Association between atopic dermatitis and hypertension: a systematic review and meta-analysis. Br J Dermatol. 2022 Feb;186(2):227-35. Abstract
148. Gerbens LAA, Hamann SAS, Brouwer MWD, et al. Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial. Br J Dermatol. 2018 Jun;178(6):1288-96. Abstract
149. Schram ME, Roekevisch E, Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011 Aug;128(2):353-9.Full text Abstract
150. Flohr C, Rosala-Hallas A, Jones AP, et al; TREAT Trial Investigators. Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial. Br J Dermatol. 2023 Nov 16;189(6):674-84.Full text Abstract
151. Li VCY, Chen KS, Yesudian BD. Subcutaneous methotrexate in the management of atopic dermatitis: a series of 12 patients. Paper presented at: American Academy of Dermatology 73rd Annual Meeting. Mar 20-24, 2015. San Francisco, CA. J Am Acad Dermatol. 2015 May 1;72(5 Suppl 1):AB75.Full text
152. Weatherhead SC, Wahie S, Reynolds NJ, et al. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol. 2007 Feb;156(2):346-51. Abstract
153. Goujon C, Bérard F, Dahel K, et al. Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol. 2006 Mar-Apr;16(2):155-8. Abstract
154. Dvorakova V, O'Regan GM, Irvine AD. Methotrexate for severe childhood atopic dermatitis: clinical experience in a tertiary center. Pediatr Dermatol. 2017 Sep;34(5):528-34. Abstract
155. Gooderham M, Lynde CW, Papp K, et al. Review of systemic treatment options for adult atopic dermatitis. J Cutan Med Surg. 2017 Jan/Feb;21(1):31-9. Abstract
156. Taylor K, Swan DJ, Affleck A, et al; U.K. Translational Research Network in Dermatology and U.K. Dermatology Clinical Trials Network. Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists. Br J Dermatol. 2017 Jun;176(6):1617-23.Full text Abstract
157. Phan K, Smith SD. Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. J Dermatolog Treat. 2020 Dec;31(8):810-4. Abstract
158. Dias-Polak D, Bergman R, Avitan-Hersh E. Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis. J Dermatolog Treat. 2019 Feb;30(1):49-51. Abstract
159. Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol. 1999 Dec;135(12):1522-5.Full text Abstract
160. Matterne U, Böhmer MM, Weisshaar E, et al. Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema. Cochrane Database Syst Rev. 2019 Jan 22;(1):CD012167.Full text Abstract
161. Ferguson L, Futamura M, Vakirlis E, et al. Leukotriene receptor antagonists for eczema. Cochrane Database Syst Rev. 2018 Oct 21;(10):CD011224.Full text Abstract
162. Pickett K, Loveman E, Kalita N, et al. Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness. Health Technol Assess. 2015 Oct;19(86):1-176.Full text Abstract
163. Chisolm SS, Taylor SL, Balkrishnan R, et al. Written action plans: potential for improving outcomes in children with atopic dermatitis. J Am Acad Dermatol. 2008 Oct;59(4):677-83. Abstract
164. de Bes J, Legierse CM, Prinsen CA, et al. Patient education in chronic skin diseases: a systematic review. Acta Derm Venereol. 2011 Jan;91(1):12-7.Full text Abstract
165. Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020 Apr 1;156(4):411-20.Full text Abstract
166. Müller S, Maintz L, Bieber T. Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs. Allergy. 2024 Jun;79(6):1501-15.Full text Abstract
167. Ruzicka T, Hanifin JM, Furue M, et al; XCIMA Study Group. Anti-Interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017 Mar 2;376(9):826-35.Full text Abstract
168. Kabashima K, Matsumura T, Komazaki H, et al; Nemolizumab-JP01 Study Group. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020 Jul 9;383(2):141-50.Full text Abstract
169. Renert-Yuval Y, Guttman-Yassky E. Systemic therapies in atopic dermatitis: the pipeline. Clin Dermatol. 2017 Jul - Aug;35(4):387-97. Abstract
170. Lee DE, Clark AK, Tran KA, et al. New and emerging targeted systemic therapies: a new era for atopic dermatitis. J Dermatolog Treat. 2018 Jun;29(4):364-74. Abstract
171. Tan XL, Thomas BR, Tan YJ, et al. Effects of systemic therapies on pruritus in adults with atopic dermatitis: a systematic review and meta-analysis. Clin Exp Dermatol. 2022 Apr;47(4):658-66. Abstract
172. Chan S, Cornelius V, Cro S, et al. Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial. JAMA Pediatr. 2020 Jan 1;174(1):29-37.Full text Abstract
173. ClinicalTrials.gov. Study to assess the efficacy and safety of orismilast in atopic dermatitis (ADESOS). NCT05469464. Oct 2023 [internet publication].Full text
174. Christoffers WA, Coenraads PJ, Svensson Å, et al. Interventions for hand eczema. Cochrane Database Syst Rev. 2019 Apr 26;(4):CD004055.Full text Abstract
175. US Food and Drug Administration. Dear Healthcare Provider letter: warning regarding use of probiotics in preterm infants. Sep 2023 [internet publication].Full text
176. Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004 May;113(5):925-31. Abstract
177. British National Formulary. Skin infections, antibacterial therapy. 2022 [internet publication].Full text
178. Medicines and Healthcare products Regulatory Agency. Topical steroids: introduction of new labelling and a reminder of the possibility of severe side effects, including topical steroid withdrawal reactions. May 2024 [internet publication].Full text
179. Ersser SJ, Cowdell F, Latter S, et al. Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev. 2014 Jan 7;(1):CD004054.Full text Abstract
180. Lavda AC, Webb TL, Thompson AR. A meta-analysis of the effectiveness of psychological interventions for adults with skin conditions. Br J Dermatol. 2012 Nov;167(5):970-9. Abstract
181. Li Y, Han T, Li W, et al. Efficacy of health education on treatment of children with atopic dermatitis: a meta-analysis of randomized controlled trials. Arch Dermatol Res. 2020 Dec;312(10):685-95. Abstract
182. Chida Y, Steptoe A, Hirakawa N, et al. The effects of psychological intervention on atopic dermatitis: a systematic review and meta-analysis. Int Arch Allergy Immunol. 2007;144(1):1-9. Abstract
183. Weber MB, Fontes Neto Pde T, Prati C, et al. Improvement of pruritus and quality of life of children with atopic dermatitis and their families after joining support groups. J Eur Acad Dermatol Venereol. 2008 Aug;22(8):992-7. Abstract
Use of this content is subject to our disclaimer